Two additional Humira biosimilars—from MYL and Samsung—are expected to launch in Europe soon.
No pricing information on Humira biosimilars in Europe has been publicly disclosed yet.
The formulation and method-of-use patents that ABBV has used to keep Humira biosimilars off the market in the US until 2023 did not stand up to challenge in Europe.